Wyze
Latest round
- Series A
Last raised
- Aug 2022
Total raised
- $30M
Investors
- 6
About Wyze
Established in 2012 and based in Zhongshan, China, Wyze is a biomedical company that focuses on the development DNT immune cell drugs., Ltd., Ltd. The company's chairman and chief scientific officer is Liming Yang. The company provides DNT immune cell drugs for patients with malignant tumors and autoimmune diseases. The product of company includes NALE antibodies, flow cytometry auxiliary reagents and CART (chimeric antigen receptor t cell therapy) cells. The business of company includes the development, production and sales of stem cells, immunobiology scientific research and diagnostic reagents. The DNT cell platform of the company adopts CART technology, gene editing technology and induced pluripotent stem cells (iPSC) technology.
Who invested in Wyze
6 investors across 2 rounds
See all investors in Wyze
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Wyze
Who invested in Wyze?
Wyze has 6 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Wyze raised?
Wyze has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Wyze last raise money?
Wyze's most recent round on record is a Series A, in Aug 2022.
What does Wyze do?
Established in 2012 and based in Zhongshan, China, Wyze is a biomedical company that focuses on the development DNT immune cell drugs.
Where is Wyze headquartered?
Wyze is headquartered in Zhongshan, China.
Which VCs invest in companies like Wyze?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Wyze's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Wyze? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.